Liquid Biopsy Market worth $11.3 billion by 2029

Browse 406 market data Tables and 56 Figures spread through 343 Pages and in-depth TOC on "Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (CTC, ctDNA, cfDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast, Prostate), Non-cancer (NIPT, Infectious)), Sample Type (Blood) - Global Forecast to 2029
Liquid Biopsy Market [https://www.prnewswire.com/news-releases/liquid-biopsy-market-worth-11-3-billion--marketsandmarkets-302139796.html] in terms of revenue was estimated to be worth $6.4 billion in 2024 and is poised to reach $11.3 billion by 2029, growing at a CAGR of 11.9% from 2024 to 2029 according to a new report by MarketsandMarkets Trademark .

In recent years, there has been substantial growth in the liquid biopsy market. The increasing burden of cancer cases globally has highlighted the urgent requirement for more effective and less invasive diagnostic tools. In this context, liquid biopsy emerges as a highly valuable solution. Unlike traditional tissue biopsies, which often involve invasive procedures and can be associated with discomfort and risks for patients, liquid biopsy offers a non-invasive alternative for detecting and monitoring cancer. Furthermore, these tests can also be used in non-invasive prenatal testing and transplantation medicine. Thus, these advantages are driving the rapid evolution and uptake of liquid biopsy products and services in disease diagnosis, treatment, and monitoring.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

In 2023, the assay kits segment held the largest share of the liquid biopsy market by product & service segment.

Based on product & service, the liquid biopsy market has been segmented into assay kits, instruments, and services. The assay kits segment dominated the liquid biopsy market in 2023. The versatility of assay kits contributes to their market dominance. These kits are adaptable to various biomarkers and analytes, accommodating the diverse needs of liquid biopsy applications, from detecting circulating tumor DNA (ctDNA) to monitoring treatment response and disease progression.

The therapy selection segment held the largest share of the liquid biopsy market by clinical application segment in 2023.

Based on clinical applications, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. In 2023, the largest share of the liquid biopsy market was held by the therapy selection segment. The growth of therapy selection as the major clinical application segment is fueled by the advantages of liquid biopsy over traditional methods with its minimally invasive, real-time monitoring capabilities across various cancer types, its integration into clinical trials and drug development processes, and its cost-effectiveness in guiding therapy selection.

North America is the largest regional market for liquid biopsy market.

The market for liquid biopsy has been divided into six key geographical regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. In 2023, North America held the predominant portion of the liquid biopsy market. The region boasts a well-developed healthcare infrastructure, including advanced diagnostic facilities, specialized oncology centers, and a skilled workforce. This infrastructure supports the integration of liquid biopsy into routine clinical practice, facilitating access for patients across various healthcare settings.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350 [https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

Liquid Biopsy Market Dynamics:

Drivers:

1. Rising incidence and prevalence of cancer2. Cancer awareness initiatives undertaken by global health organizations3. Benefits of liquid biopsy over traditional biopsy procedures

Restraints:

1. Lower sensitivity of certain liquid biopsy procedures

Opportunities:

1. Growing significance of companion diagnostics2. Growth opportunities in emerging countries

Challenge:

1. Unclear reimbursement scenario

Key Market Players of Liquid Biopsy Industry:

The major players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Myriad Genetics, Inc. (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Guardant Health (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), Sysmex Corporation (Japan), Biocept, In. (US), mdxhealth (US), Personalis, Inc. (US), NeoGenomics Laboratories (US), Epigenomics AG (Germany), ANGLE plc (UK), Menarini-Silicon Biosystems (Italy), Vortex Biosciences (US), Bio-Techne (US), MedGenome (US), Mesa Labs, Inc. (US), Laboratory Corporation of America Holdings (US), Freenome Holdings, Inc. (US), Strand (India), LungLife AI, Inc. (US), and Lucence Health Inc. (US).

The break-up of the profile of primary participants in the liquid biopsy market:

* By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
* By Designation: C-level - 27%, D-level - 18%, and Others - 55%
* By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=13966350 [https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=13966350&utm_source=ABnewswire&utm_campaign=Paid&utm_content=Referral]

Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=liquid-biopsy-market-worth-113-billion-by-2029]
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html



This release was published on openPR.